Immuno-oncology Treatment Devices and Drugs Market Analysis

The immuno-oncology treatment devices and drugs market is segmented based on treatment type into immune checkpoint inhibitors, immune system modulators, cancer vaccines, oncolytic virus, and others, out of which, the immune checkpoint inhibitors segment is anticipated to grab the largest market share by the end of 2029 on account of its high level of specificity and lesser side-effects. Moreover, increasing government approval for new treatments and drugs globally is also projected to contribute to the growth of the segment during the forecast period.

On the basis of indication, the breast cancer segment in the immuno-oncology treatment devices and drugs market is projected to grow with a high CAGR over the forecast period. Obesity, lack of physical exercise, overexposure to radiation, and increased alcohol consumption are some of the major risk factors causing breast cancer in females. According to Globocan report 2020, the incidence rate of breast cancer was 5.20% which accounted for 2.26 million new cases globally with a mortality rate of 6.9%.

Based on end-user, the hospital segment held the largest share in the immuno-oncology treatment devices and drugs market on the back of increasing patient influx and increasing spending by the hospitals on immuno-oncological treatments. 

Our in-depth analysis of the global market includes the following segments: